Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibito…

Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Revolution Medicines, Inc.NCT06162221

Phase 2

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered …

Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung Cancer+5 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression f…

Non-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IVNon Small Cell Lung Cancer+2 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, DavisNCT07250477

Phase 1

A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the additi…

Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Washington University School of MedicineNCT07355205

Phase 2

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have …

Non-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Case Comprehensive Cancer CenterNCT07104630

Phase 3

A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult pa…

Small Cell Lung Cancer Extensive StageSmall-cell Lung CancerSmall Cell Carcinoma+5 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

SystImmune Inc.NCT07625644